SCHEMBL5412928

SCHEMBL5412928

C#CCOc1cc(Oc2cccc(OC)c2)ncn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.46
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 1/20 0.46
BRCA1 P38398 1/20 0.46
HBB P68871 1/20 0.46
KMT2A Q03164 1/20 0.46
HSD17B10 Q99714 1/20 0.46
MTNR1B P49286 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MAOB P27338 5/20 0.40
GRM5 P41594 3/20 0.39
DCK P27707 1/20 0.39
RAB9A P51151 2/20 0.37
MAOA P21397 1/20 0.37
NPC1 O15118 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5407437 0.87 L3MBTL1 (0.42) MEN1ALDH1A1KMT2ASMN1; SMN2L3MBTL1
SCHEMBL5411167 0.86 MAP4K4 (0.45) MEN1ALDH1A1KMT2ASMN1; SMN2L3MBTL1
SCHEMBL5413305 0.84 SMN1; SMN2 (0.54) ALDH1A1SMN1; SMN2L3MBTL1MAOBRAB9A
SCHEMBL5413024 0.83 MAP4K4 (0.45) SMN1; SMN2L3MBTL1MAOBGRM5DCK
SCHEMBL5415271 0.83 MAP4K4 (0.45) SMN1; SMN2L3MBTL1MAOBRAB9AMAOA
SCHEMBL12826224 0.82 ALDH1A1 (0.55) KDM4EMEN1ALDH1A1BRCA1HBB
SCHEMBL5410817 0.80 L3MBTL1 (0.49) KDM4EALDH1A1L3MBTL1MAPT
SCHEMBL5415938 0.79 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2L3MBTL1MAOBDCK
SCHEMBL791878 0.78 MAOB (0.54) MTNR1BMAOBGRM5MAOALMNA
SCHEMBL5410450 0.78 SMN1; SMN2 (0.47) KDM4EMEN1ALDH1A1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7291730-B2 Pyrimidine compounds and their use SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-11-06 US disclosed
US-20050107609-A1 Pyrimidine compounds and their use SUMITOMO CHEMICAL COMPANY 2005-05-19 US disclosed
US-6838463-B2 Pyrimidine compounds and their use SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2005-01-04 US disclosed
EP-1366026-B1 PYRIMIDINE COMPOUNDS AND THEIR USE AS PESTICIDES SUMITOMO CHEMICAL CO (JP) 2004-12-01 EP disclosed
US-20040077669-A1 Pyrimidine compounds and their use SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2004-04-22 US disclosed
EP-1366026-A2 PYRIMIDINE COMPOUNDS AND THEIR USE SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2003-12-03 EP disclosed
WO-2002024663-A2 PYRIMIDINE COMPOUNDS AND THEIR USE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107609-A1 Pyrimidine compounds and their use TYMP, TYMS, UMPS KDM4E 1716/4885MEN1 2555/4885ALDH1A1 783/4885
US-20040077669-A1 Pyrimidine compounds and their use TYMP, TYMS, DPYD KDM4E 1535/4885MEN1 2039/4885ALDH1A1 654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.